Insilico Medicine to present at the 2019 Bio Asia-Taiwan
Insilico Medicine to present its latest research at the 2019 BIO Asia-Taiwan Conference and Exhibition
Credit: Insilico Medicine
Thursday, July 18, 2019 – Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest research at The Bio Asia-Taiwan 2019 on July 25th in Taipei. Insilico Medicine is also very proud to be one of the exhibitors at the event, which will give a unique opportunity to present our brand and to communicate with the entrepreneurs and researchers, interested in applying artificial intelligence to drug discovery.
The Bio Asia-Taiwan 2019 International Conference, July 24 -28, taking place in Taipei in Nangang Exhibition Hall, will bring together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia to meet and explore business opportunities with Taiwan’s emerging biotech sector. Themed “Biotech as the Next Growth Engine for Asia”, this year’s event will attract more than 1,500 attendees from 25 countries who will gather together to foster the development of the industry.
“We are proud to be an exhibitor at the Bio Asia-Taiwan 2019 and provide our local team with a chance to learn and exchange ideas. Our vision is to create a fully automated end-to-end pipeline to eliminate bottlenecks, maximize efficiency and streamline early drug discovery. AI is the future of the industry that has all the potential to transform and combat the issues of a complex drug discovery process. If you are in Taipei on July 25th, please register for Bio Asia-Taiwan 2019 Conference, visit our booth and consider joining the effort,” said Artur Kadurin, CEO of Insilico Taiwan.
You will find Insilico Taiwan at the Booth #M906, 4F, in the Nangang Exhibition Hall.
For further information, images or interviews, please contact:
Contact: Artur Kadurin
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
About Insilico Medicine
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/